跳轉至內容
Merck
全部照片(1)

文件

SML2624

Sigma-Aldrich

Dexlansoprazole

≥98% (HPLC)

同義詞:

(R)-(+)-Lansoprazole, (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C16H14F3N3O2S
CAS號碼:
138530-94-6
分子量：:
369.36
MDL號碼:
MFCD16294176
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D +142 to +158°, c = 1 in chloroform-d

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

InChI 密鑰

MJIHNNLFOKEZEW-RUZDIDTESA-N

生化／生理作用

Dexlansoprazole is a proton pump inhibitor. It is the active enantiomer of lansoprazole used to treat gastroesophageal reflux disease (GERD).

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Karen E Hansen et al.
Gastroenterology, 156(4), 926-934 (2018-11-18)
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium
Khean Lee Goh et al.
Journal of neurogastroenterology and motility, 22(3), 355-366 (2016-03-05)
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務